Assembly Biosciences Inc (NASDAQ:ASMB) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $16.77 and last traded at $17.58, with a volume of 3417 shares traded. The stock had previously closed at $18.20.

A number of equities research analysts recently issued reports on the company. BidaskClub upgraded Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, February 14th. Zacks Investment Research upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research report on Thursday, February 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. Assembly Biosciences presently has a consensus rating of “Hold” and a consensus price target of $47.00.

The company has a market cap of $464.83 million, a PE ratio of -4.45 and a beta of 1.77.

Several large investors have recently made changes to their positions in ASMB. First Trust Advisors LP acquired a new stake in Assembly Biosciences in the 3rd quarter valued at approximately $1,624,000. Wells Fargo & Company MN raised its position in Assembly Biosciences by 18.3% in the 3rd quarter. Wells Fargo & Company MN now owns 64,444 shares of the biopharmaceutical company’s stock valued at $2,394,000 after buying an additional 9,977 shares during the last quarter. JPMorgan Chase & Co. raised its position in Assembly Biosciences by 3.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 82,769 shares of the biopharmaceutical company’s stock valued at $3,074,000 after buying an additional 3,022 shares during the last quarter. Swiss National Bank raised its position in Assembly Biosciences by 21.9% in the 3rd quarter. Swiss National Bank now owns 35,100 shares of the biopharmaceutical company’s stock valued at $1,304,000 after buying an additional 6,300 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in Assembly Biosciences in the 3rd quarter valued at approximately $540,000. 83.62% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Assembly Biosciences (ASMB) Sets New 12-Month Low at $16.77” was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/assembly-biosciences-asmb-sets-new-12-month-low-at-16-77/2917311.html.

About Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Recommended Story: What is the price-to-earnings growth (PEG) ratio?

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.